[Lipid profile of atazanavir]
1Servicio de Infecciones, Hospital Clínic-Institut d'Investigaciones Biomèdiques August Pi i Sunyer, Universidad de Barcelona, España. esteban@fundsoriano.es
Enfermedades Infecciosas Y Microbiologia Clinica
|February 2, 2010
Summary
Antiretroviral therapy can increase cardiovascular risk, but stopping treatment is riskier. Atazanavir offers a lipid-friendly option for HIV patients prioritizing cardiovascular health.
Area of Science:
- Pharmacology and Toxicology
- Cardiovascular Medicine
- Infectious Diseases
Context:
- Antiretroviral therapy (ART), especially protease inhibitors (PIs), is linked to increased cardiovascular disease (CVD) risk in HIV-positive individuals.
- Managing dyslipidemia and CVD risk in HIV patients involves recommendations similar to the general population, with a preference for lipid-neutral treatments.
- Stopping ART poses a greater risk than managing potential side effects.
Purpose:
- To evaluate the metabolic and cardiovascular profile of atazanavir compared to other protease inhibitors in HIV treatment.
- To highlight atazanavir's distinct characteristics regarding lipid metabolism and adipose tissue effects.
- To identify the role of atazanavir in HIV management when cardiovascular risk reduction is a priority.
Summary:
- Atazanavir, unlike other PIs, does not elevate total cholesterol, LDL-cholesterol, or triglycerides in various treatment settings (initial, rescue, simplification).
- In vitro and clinical studies consistently demonstrate atazanavir's favorable lipid profile.
- These findings support atazanavir as an attractive option for specific HIV-infected patients concerned about cardiovascular risk.
Impact:
- Provides a safer antiretroviral treatment option for HIV patients at high cardiovascular risk.
- Informs clinical decision-making for selecting ART regimens that minimize metabolic complications.
- Contributes to improved long-term health outcomes for HIV-infected individuals by mitigating treatment-associated cardiovascular risks.
Related Concept Videos
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:24Lipid Absorption
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
01:16Hepatic Drug Excretion: Influencing Factors
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
01:09Hepatic Drug Clearance: Effect of Protein Binding
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...